For two years, the most effective weight-loss medicines in history have had a velvet rope around them. The list prices ran over a thousand dollars a month. Insurance said no more often than yes. Medicare was legally barred from covering weight loss at all. The drugs worked; the wallet didn't.
This winter the rope moved. Under deals struck between the White House and the two big manufacturers in November, the cash price for the flagship injectables drops to roughly $346 to $350 a month — about half what uninsured patients faced before — with government programs paying around $245. A federal direct-purchase website launched this month to sell at those prices. Future pill versions are promised at about $150. And for the first time, Medicare will cover obesity treatment for some patients starting mid-year, with a $50 copay.
Those are the numbers. My desk's question, as always, is what the numbers do to the line outside the pharmacy.
Some of it is real relief. Three hundred fifty dollars is still a car payment, but it is a different universe from a thousand. For the middle-income patient with no coverage — the person who was splitting doses or buying from questionable compounding pharmacies — the discount is the difference between treatment and no treatment. Public-health researchers have estimated that tens of millions of Americans meet the clinical bar for these drugs. Price was the biggest single gate. The gate just got wider.
But a few pieces of fine print belong in the story, because they decide who actually walks through.
First, cash price is not coverage. A deal that lowers the sticker helps the person who can pay cash monthly. It does nothing by itself for the family that cannot spare $350 any more than it could spare $1,000. The Medicare piece is the structurally bigger change — a $50 copay is a genuinely open door — but it begins mid-year, for some patients, under criteria still being written. Watch the criteria. Eligibility rules are where access quietly gets rationed after the cameras leave.
Second, a discount negotiated by press conference is a discount that can un-happen. None of this went through the slow machinery of law. The prices exist because two companies and one administration currently want them to. Patients now planning years of treatment — these are long-haul medicines; stop them and the weight generally returns — are building on an agreement, not a statute.
Third, the pharmacies and clinics downstream have to absorb the wave. A drug that tens of millions of people newly afford is a drug that tens of millions of people newly request. Supply held up better in 2025 than in the shortage years before it, but primary care did not get less crowded. Prescriptions require prescribers. The next bottleneck is an appointment.
None of this is a reason to shrug at the news. It is the biggest affordability move on any drug class in years, and it lands on a condition that affects two in five American adults and gets moralized more than it gets treated. My colleague Gawon has written about what these medicines are doing to the culture's ideas about willpower. The access ledger is simpler and colder: for two years the miracle had a velvet rope, and the rope was income.
The rope moved. Whether it moved enough — check back with the person at the counter in July, holding a Medicare card and a fifty-dollar bill, finding out.
